

# ANNOUNCEMENT



SEA: NZX and Media Release

24 September 2015

## **SeaDragon shareholders rights offer closes tomorrow**

New Zealand's leading refiner and blender of high-quality fish oils SeaDragon Limited (NZX:SEA) reminds shareholders that its 3-for-5 renounceable rights offer closes tomorrow at 5.00pm.

SeaDragon is seeking to raise up to \$9.09 million in new equity capital to fund the ongoing construction of the company's new Omega-3 plant in Nelson, add a fractionation plant to the facility, upgrade its existing Omega-2 plant, pay the costs of the rights offer and meet working capital requirements.

**Eligible shareholders should have received a copy of the offer document and their letter of entitlement and acceptance detailing their rights to subscribe for rights under the Offer.**

**If any eligible shareholder has not received details of their rights or a copy of the offer document by mail or by email, or has misplaced their copy, they should contact Link Market Services on +64 9 375 5998 or [applications@linkmarketservices.co.nz](mailto:applications@linkmarketservices.co.nz)**

Eligible shareholders may take the following actions in relation to the rights offer:

- accept all or part of their rights; or
- do nothing with all or part of their rights.

Eligible shareholders who take up all their rights may also apply for additional rights under the offer's oversubscription facility.

If eligible shareholders do nothing with their rights before the closing date, then they will lapse and those shareholders will not be able to subscribe for any new shares or options under the rights or realise any other value for their rights (except as provided for in relation to the shortfall book build due to take place next week).

Those eligible shareholders who have already completed and returned their application forms with payment to Link Market Services need not take any further action.

**Any eligible shareholder wishing to accept the Offer and take up all or some of their rights should do so promptly, to ensure their application and payment is received by Link Market Services, by 5.00pm on 25 September 2015.**

Further details of the Offer and the oversubscription facility are set out in the offer document.



The Shortfall book build, for SEA securities that are attributable to unexercised rights, as described in the offer document, will open at 10am on Tuesday 29 September, and close at 3pm, on the same day.

Investors interested in participating in the Shortfall book build process may do so by contacting an NZX Primary Market Participant Firm, or contacting the Lead Manager directly (details below). All participants must be Eligible Bookbuild Investors as described in the offer document.

#### Offer timetable

Closing Date - last day for receipt of the completed entitlement and acceptance form with payment.	5:00pm Friday 25 September 2015
Shortfall book build	Tuesday 29 September 2015
New shares and options allotted	Friday 2 October 2015
Expected date of quotation of new shares	Friday 2 October 2015
Shareholder statements dispatched to successful applicants no later than:	Thursday 8 October 2015

#### Contact:

Colin Groves  
Chairman  
Tel: +64 21 928 003

Richard Inder  
Merlin Consulting  
Tel: +64 21 645 643

#### Book build Contact Details:

Beale Capital Consultants Limited  
[James.beale@capitalconsultants.co.nz](mailto:James.beale@capitalconsultants.co.nz)  
+64 29 5774712

#### About SeaDragon [www.seadragon.co.nz](http://www.seadragon.co.nz)

SeaDragon (NZX:SEA) is New Zealand's largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils. Our oils are sourced from fish caught in the clean and pure waters around New Zealand, in the Southern Ocean, and elsewhere. We have more than 20 years' experience processing fish oils and we are recognised for the quality and purity of our products. We supply health supplement manufacturers around the world to meet the burgeoning demand for pure, high-quality fish oils, which are scientifically proven to deliver significant human health benefits such as lowering the risk of heart disease, improving brain function and joint health. The majority of our supply is exported.